Avoro Capital Advisors Reduces $6M in Lexeo Therapeutics, Inc. ($LXEO)

Avoro Capital Advisors has cut its position in LXEO by a substantial 43%, according to its latest Form 13F filing with the SEC on May 15, 2026. The fund reduced its holdings by 1,425,000 shares, leaving it with 1,875,000 shares valued at approximately $8.19 million. This move reflects Avoro's reduced confidence in the company during the reporting period.

What Changed in Avoro Capital Advisors' LXEO Position

Avoro Capital Advisors significantly reduced its stake in LXEO, trimming its holdings from 3,300,000 shares to 1,875,000 shares. This represents a decrease of 1,425,000 shares, or about 43%. The remaining position is valued at approximately $8.19 million as of the end of the reporting period.

Other Institutional Activity in LXEO

In addition to Avoro's reduction, other institutional investors made notable moves in LXEO. Paradigm Biocapital Advisors LP increased its holdings by 1,420,936 shares, bringing its total to 6,184,134 shares valued at $35.5 million. BlackRock, Inc. added 203,308 shares, ending with 5,110,871 shares worth approximately $29.3 million. Affinity Asset Advisors, LLC also grew its position by 1,850,211 shares, totaling 5,050,211 shares valued at about $28.9 million. Conversely, Janus Henderson Group PLC reduced its holdings by 533,206 shares, leaving it with 4,976,429 shares valued at $28.5 million.

LXEO Stock Snapshot

Shares of LXEO recently traded around $4.37. The company has attracted significant attention from institutional investors, as evidenced by the recent activity. With a market capitalization not specified in the data, the stock's recent performance and analyst ratings remain critical for investors.

Insider Buying and Selling at Lexeo Therapeutics, Inc.

There has been notable insider activity at LXEO. On May 18, 2026, Chief Operating Officer Jose Manuel Otero sold 1,302 shares at an average price of $5.07. On the same day, CEO Richard Nolan sold 3,342 shares at $5.06. Earlier, on April 6, 2026, Nolan sold 55,000 shares at $5.69 under a planned sale. However, on March 13, 2026, Nolan bought 2,623 shares at $2.644, and Otero purchased 5,930 shares at the same price.

Analysts Set New Price Targets

Analysts continue to show interest in LXEO. On May 11, 2026, Chardan Capital maintained its 'buy' rating with a $17 price target. Earlier in the year, HC Wainwright & Co. also maintained a 'buy' rating, setting a $10 target. These ratings reflect ongoing positive sentiment from analysts.

About LXEO

LXEO is a company operating in a sector not specified in the data. It focuses on delivering innovative solutions and products tailored to its industry. The company is led by CEO Richard Nolan and COO Jose Manuel Otero, who oversee its strategic direction and operations.

Bottom Line

Avoro Capital Advisors' decision to cut its stake in LXEO by 43% is a significant move that investors are likely to watch closely. The reduction, as reported in the 13F filing, provides insight into the fund's shifting confidence in the company. While other institutional investors have increased their positions, the analyst community maintains a generally positive outlook on LXEO. As always, it's essential to remember that 13F filings are backward-looking and may not reflect current positions.